Halo Collective Past Earnings Performance
Past criteria checks 0/6
Halo Collective's earnings have been declining at an average annual rate of -48.7%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 23% per year.
Key information
-48.7%
Earnings growth rate
61.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 23.0% |
| Return on equity | -126.4% |
| Net Margin | -333.9% |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Halo Collective makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 28 | -95 | 38 | 0 |
| 30 Jun 22 | 32 | -99 | 43 | 0 |
| 31 Mar 22 | 34 | -99 | 44 | 0 |
| 31 Dec 21 | 36 | -95 | 42 | 0 |
| 30 Sep 21 | 33 | -54 | 39 | 0 |
| 30 Jun 21 | 31 | -47 | 31 | 0 |
| 31 Mar 21 | 27 | -42 | 25 | 0 |
| 31 Dec 20 | 22 | -41 | 22 | 0 |
| 30 Sep 20 | 19 | -33 | 24 | 0 |
| 30 Jun 20 | 20 | -35 | 27 | 0 |
| 31 Mar 20 | 24 | -33 | 26 | 0 |
| 31 Dec 19 | 28 | -28 | 24 | 0 |
| 30 Sep 19 | 28 | -17 | 17 | 0 |
| 30 Jun 19 | 25 | -17 | 14 | 0 |
| 31 Mar 19 | 17 | -15 | 11 | 0 |
| 31 Dec 18 | 11 | -14 | 9 | 0 |
| 30 Sep 18 | 10 | -15 | 11 | 0 |
| 30 Jun 18 | 10 | -11 | 10 | 0 |
| 31 Mar 18 | 10 | -10 | 10 | 0 |
| 31 Dec 17 | 10 | -9 | 9 | 0 |
| 31 Dec 16 | 5 | 0 | 1 | 0 |
Quality Earnings: A9KN is currently unprofitable.
Growing Profit Margin: A9KN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A9KN is unprofitable, and losses have increased over the past 5 years at a rate of 48.7% per year.
Accelerating Growth: Unable to compare A9KN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A9KN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.8%).
Return on Equity
High ROE: A9KN has a negative Return on Equity (-126.35%), as it is currently unprofitable.